Stocks · News reference
Zymeworks has partnered with Roche to develop ZW209, a trispecific T-cell engager targeting DLL3, in a deal potentially worth over $800 million.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Faeth Therapeutics has appointed Adam Schayowitz, Ph.D., MBA, the Executive Vice President and Head of Research and Development at Zymeworks, to its Board of Directors.
Zymeworks reported new clinical data from its Phase 1 study of ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing anti-tumor activity in platinum-resistant ovarian cancer.
Zymeworks announced a global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3. Zymeworks will receive $55 million upfront and $40 million upon Phase 1b initiation, with potential for up to $718 million in additional milestone payments and tiered royalties on future net sales. Zymeworks will conduct the Phase 1a trial while Roche funds it and handles subsequent development and commercialization.